Meningitis Vaccines Market, By Type (Bivalent, Quadrivalent, and Others), By Brand (MenQuadfi, Menveo, Trumenba, Bexsero, and Others), By Serotype (Serotype A, Serotype B, Serotype C, Serotype W-135, and Others), By Sales Channel (Private and Public), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Nov 2024

Code : CMI5042

Pages :359

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

On June 13, 2024, Gavi, the Vaccine Alliance, a public-private partnership established in 2000, aimed at increasing access to vaccines in low-income countries, announced that the lower-income countries it supports can now apply to introduce four new vaccines: a preventive Ebola vaccine, a human rabies vaccine for post-exposure treatment, a multivalent meningococcal conjugate vaccine, and a hepatitis B birth dose. This initiative aims to strengthen immunization efforts in these areas and enhance health outcomes.
On April 16, 2024, GSK plc, a leading global biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) accepted the review of its Biologics License Application (BLA) for the 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate
On April 15, 2024, Serum Institute of India Pvt. Ltd., a biotechnology company, announced a significant agreement with the University of Oxford to develop a Meningitis-B vaccine. This collaboration aims to create a chimeric protein-based vaccine that addresses the shortcomings of existing Men-B vaccines regarding efficacy, safety, and coverage.
In October 2023, Pfizer, Inc., a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved PENBRAYA, the first and only pentavalent vaccine designed to protect against the most prevalent serogroups responsible for meningococcal disease in adolescents and young adults aged 10 to 25 years